Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
NCT00338767
Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users
NCT00228007
Measurement-based Care for Depression in Resource-Poor Settings
NCT02916238
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder
NCT03230682
Augmented Human Intelligence in Major Depressive Disorder
NCT04355650
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Imipramine hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* May have been alcoholic or drug abuser 6 months previous.
* Unspecified
* CD4 Unspecified.
Exclusion Criteria
* Non ambulatory patients or those requiring extensive help in self care are excluded.
* Current alcohol or drug abuse.
* Unspecified
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GEIGY Pharmaceuticals
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frances A
Role: STUDY_CHAIR
Manning D
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York Hosp - Cornell Med Ctr
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87-DEP
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.